[Edaily Reporter Shin Ha-yeon ] EVERYBOT Inc.(270660)announced on the 23rd that it has signed a Memorandum of Understanding (MOU) with WiseAI, a medical artificial intelligence (AI) platform company, to jointly develop and commercialize an AI-based smart senior care platform.
Under this agreement, the two companies plan to combine EVERYBOT Inc.’s AI-powered autonomous electric wheelchairs and autonomous robot technology with WiseAI’s medical-specific AI platform technology to jointly develop and commercialize smart care services for the elderly and people with limited mobility. (Photo courtesy of EVERYBOT Inc.) WiseAI is a medical AI platform company that offers the healthcare-specific AI solution “AURA/LAM,” the AI call and chatbot service “AiU,” and automated patient management solutions. These solutions have been adopted by numerous medical institutions, and the company also has experience executing government research and development (R&D) projects.
EVERYBOT Inc. is expanding its senior care business—including electric wheelchairs, care robots, and personal mobility devices—based on AI-powered autonomous driving technology. Through this collaboration, the company aims to develop service models that integrate AI, mobility, and digital healthcare technologies and strengthen its competitive edge in the smart senior care sector.
EVERYBOT Inc. stated, “Based on technologies to be developed in the future, we plan to expand our business into various sectors—including the senior care market, long-term care facilities, medical institutions, and public welfare—while also actively pursuing government R&D projects and entering global markets.”
The way global private equity fund (PEF) managers invest in rental housing is evolving. Previously, most cases involved directly purchasing individual properties. However, transactions have recently e…
SK hynix has drawn a clear line regarding reports that it is pursuing the sale of its stake in its Chongqing, China, plant, stating, “Nothing has been finalized.” This is the company’s response to a r…
Medy-Tox Inc.(086900)Medytox continued its revenue growth in the second quarter of this year, driven by expanded overseas sales of botulinum toxin and dermal fillers, as well as the successful market …